Beijing Tricision Biotherapeutic

Tricision Biotherapeutic is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of next-generation multi-specific antibodies for cancer immunotherapy. The company leverages its proprietary Tri-specific T-cell Engager (TriTE) platform to design therapies that simultaneously target multiple tumor antigens and activate T-cells. This approach aims to overcome the limitations of current bispecific treatments, such as low efficacy in solid tumors and safety concerns. Tricision's pipeline focuses on high-unmet-need indications in oncology, including both solid tumors and hematological malignancies. Led by industry veterans with extensive experience in biologics development, the company is dedicated to advancing precision medicine through innovative protein engineering. The company has successfully secured significant venture capital funding from prominent investors to accelerate its lead programs into clinical trials.